Receptron Begins Phase I Clinical Trial for Prevention of Thrombocytopenia

Cancer Chemotherapy Induced Platelet Deficiency



Apr 02, 2001, 01:00 ET from Receptron, Inc.

    MOUNTAIN VIEW, Calif., April 2 /PRNewswire/ -- Receptron, Inc., a
 privately held biopharmaceutical company, today announced that it has
 initiated clinical trials of its first potential drug candidate RCN-01303.
 The Phase I study is being conducted at the Greenebaum Cancer Center at the
 University of Maryland in Baltimore, and is primarily focused on preventing
 platelet deficiency, a severe complication induced by cancer chemotherapy.
     Receptron scientists discovered RCN-01303, which is based on the company's
 proprietary hormone receptor technology.  Patents have been filed on both the
 compound and the technology and Receptron expects to receive strong patent
 protection on its inventions.  The compound acts by a novel mechanism, which
 is believed to modulate the endogenous thrombopoietin (TPO) receptor.  TPO is
 a human hormone that stimulates platelet production.
     In animal studies, RCN-01303 has been shown to be highly effective in
 preventing the development of thrombocytopenia induced by chemotherapeutic
 agents, without severe side effects.  In addition, administration of the
 compound when thrombocytopenia had already developed reduced the likelihood of
 progression to more severe thrombocytopenia.  Furthermore, RCN-01303 appears
 to stimulate platelet production after the administration of chemotherapeutic
 agents has been initiated, suggesting its utility as a treatment as well as a
 preventative.
     "RCN-01303 is believed to activate platelet production through a novel
 mechanism and in the absence of normal platelet stimulating hormone (TPO),"
 stated Lennart Olsson, MD, president, chief executive officer and founder of
 Receptron.  "Further evidence suggests that, due to its unique mechanism of
 action, RCN-01303 enhances the efficiency of TPO, both natural circulating
 (endogenous) and injected (exogenous).  Thus, it may offer benefit both when
 used alone or in combination with recombinant TPO."
     Initially, RCN-01303 is being studied in patients receiving cancer
 chemotherapy.  However, it is possible that the compound may be useful in
 other conditions associated with platelet deficiency.
     The worldwide market for drugs to treat thrombocytopenia due to cancer
 chemotherapy is more than $1 billion.  There is significant need for new
 treatments, as current therapy with platelet transfusion is very expensive,
 often impractical, and associated with potential transfusion reactions and
 complications.  In 1998, Receptron entered into a worldwide, exclusive license
 for the development and commercialization of RCN-01303 with Pliva, a
 Croatia-based pharmaceutical company.  Under the terms of the agreement, Pliva
 is funding the clinical program and Receptron will receive milestone payments
 and royalties on product sales.
     Receptron's receptor technology is broadly applicable and has allowed
 development of similar compounds in relation to other hormone receptors such
 as growth hormone, anemia (EPO receptor), autoimmune diseases, diabetes, etc.
 Receptron is pursuing the discovery and development of such oral compounds and
 recently completed an exclusive license with Pharmacia Corporation in the area
 of growth hormone.  Receptron is also developing a compound to replace
 erythropoietin (not yet partnered).  The technology has also allowed
 development of similar "small molecules" that may be used to deliver the
 bioactive compounds orally.
     Receptron, Inc. is a privately held biotechnology company, located in
 Mountain View, California.  The company's proprietary technology allows for
 development of drugs to activate -- and inactivate -- hormone reactions.  It
 is expected that the technology is applicable to a very broad range of
 receptors due to its novel mechanism of action.  The technology may be used to
 develop both stimulants (agonists) and inhibitors (antagonists) of receptor
 activity.  Current development has focused on growth hormone, which is
 licensed to Pharmacia; erythropoietin for small molecule agonists; and for
 IL-4 and EGF antagonists.  Receptron is seeking collaborative partners for
 some of its receptor targets.
     For additional information, please contact Dr. Lennart Olsson at
 650-988-9413 ext. 102, or Dr. Tatjana Naranda at 650-988-9413 ext. 108.
 
 

SOURCE Receptron, Inc.
    MOUNTAIN VIEW, Calif., April 2 /PRNewswire/ -- Receptron, Inc., a
 privately held biopharmaceutical company, today announced that it has
 initiated clinical trials of its first potential drug candidate RCN-01303.
 The Phase I study is being conducted at the Greenebaum Cancer Center at the
 University of Maryland in Baltimore, and is primarily focused on preventing
 platelet deficiency, a severe complication induced by cancer chemotherapy.
     Receptron scientists discovered RCN-01303, which is based on the company's
 proprietary hormone receptor technology.  Patents have been filed on both the
 compound and the technology and Receptron expects to receive strong patent
 protection on its inventions.  The compound acts by a novel mechanism, which
 is believed to modulate the endogenous thrombopoietin (TPO) receptor.  TPO is
 a human hormone that stimulates platelet production.
     In animal studies, RCN-01303 has been shown to be highly effective in
 preventing the development of thrombocytopenia induced by chemotherapeutic
 agents, without severe side effects.  In addition, administration of the
 compound when thrombocytopenia had already developed reduced the likelihood of
 progression to more severe thrombocytopenia.  Furthermore, RCN-01303 appears
 to stimulate platelet production after the administration of chemotherapeutic
 agents has been initiated, suggesting its utility as a treatment as well as a
 preventative.
     "RCN-01303 is believed to activate platelet production through a novel
 mechanism and in the absence of normal platelet stimulating hormone (TPO),"
 stated Lennart Olsson, MD, president, chief executive officer and founder of
 Receptron.  "Further evidence suggests that, due to its unique mechanism of
 action, RCN-01303 enhances the efficiency of TPO, both natural circulating
 (endogenous) and injected (exogenous).  Thus, it may offer benefit both when
 used alone or in combination with recombinant TPO."
     Initially, RCN-01303 is being studied in patients receiving cancer
 chemotherapy.  However, it is possible that the compound may be useful in
 other conditions associated with platelet deficiency.
     The worldwide market for drugs to treat thrombocytopenia due to cancer
 chemotherapy is more than $1 billion.  There is significant need for new
 treatments, as current therapy with platelet transfusion is very expensive,
 often impractical, and associated with potential transfusion reactions and
 complications.  In 1998, Receptron entered into a worldwide, exclusive license
 for the development and commercialization of RCN-01303 with Pliva, a
 Croatia-based pharmaceutical company.  Under the terms of the agreement, Pliva
 is funding the clinical program and Receptron will receive milestone payments
 and royalties on product sales.
     Receptron's receptor technology is broadly applicable and has allowed
 development of similar compounds in relation to other hormone receptors such
 as growth hormone, anemia (EPO receptor), autoimmune diseases, diabetes, etc.
 Receptron is pursuing the discovery and development of such oral compounds and
 recently completed an exclusive license with Pharmacia Corporation in the area
 of growth hormone.  Receptron is also developing a compound to replace
 erythropoietin (not yet partnered).  The technology has also allowed
 development of similar "small molecules" that may be used to deliver the
 bioactive compounds orally.
     Receptron, Inc. is a privately held biotechnology company, located in
 Mountain View, California.  The company's proprietary technology allows for
 development of drugs to activate -- and inactivate -- hormone reactions.  It
 is expected that the technology is applicable to a very broad range of
 receptors due to its novel mechanism of action.  The technology may be used to
 develop both stimulants (agonists) and inhibitors (antagonists) of receptor
 activity.  Current development has focused on growth hormone, which is
 licensed to Pharmacia; erythropoietin for small molecule agonists; and for
 IL-4 and EGF antagonists.  Receptron is seeking collaborative partners for
 some of its receptor targets.
     For additional information, please contact Dr. Lennart Olsson at
 650-988-9413 ext. 102, or Dr. Tatjana Naranda at 650-988-9413 ext. 108.
 
 SOURCE  Receptron, Inc.